- Policy
- Ppl willing to pay max ₩13.52 mil. for one-shot therap
- by Kim, Jung-Ju Aug 26, 2021 05:58am
- Over 75% of the public responded that high-priced innovative new drugs, or so-called ‘one-shot treatments,’ should be covered by the National Health Insurance. As to the maximum price the public was willing to pay for such treatments, the average price was &8361;13.52 million, and the most amount of respondents - 33.3% - agreed to the price.
- Company
- GSK will supply Fluarix Tetra through Kwang Dong
- by Aug 26, 2021 05:58am
- GSK has signed a contract with Kwang Dong, which has disrupted discussions between SK Bioscience and Fluarix Tetra. GSK announced on the 24th that it has advertised and signed a joint sales contract with the flu vaccine Fluarix Tetra as a new partner. Initially, GSK discussed co-sale of Fluarix Tetra with SK Bioscience, which decided n
- Policy
- Drugs caught in rebates for 2 years can be replaced by fines
- by Kim, Jung-Ju Aug 26, 2021 05:58am
- Among the insurance drugs caught as rebates, drugs that have been claimed for two consecutive years based on the date of disposal are expected to be replaced by fines. It belongs to cases that may cause inconvenience in patient care, not to harm public welfare. In the case of fines on these drugs, the rate will be increased by varying the upp
- Company
- MSD’s Keytruda becomes the 'symbol' of cancer immunotherapy
- by Eo, Yun-Ho Aug 25, 2021 05:57am
- “Reinforcing the body’s immunity to attack cancer cells” By some, the idea was regarded improbable. Not many were convinced that immunotherapy would rise to the position it is in now. Even without reference to the famous story of how the former US president Jimmy Carter cured melanoma with immunotherapy, cancer immunotherapy has
- Policy
- Will the voluntary recovery of AZBT be expanded?
- by Lee, Tak-Sun Aug 25, 2021 05:57am
- More and more drugs are voluntarily recovered due to the excessive detection of impurities AZBT(Azido Methyl Bipheny Ttetrazole). On the 6th, the recovery of items produced before 2021 among three items containing Irvesartan (Rovelito, CoAprovel, and Arovel) was decided, and AZBT was also detected in a Valsartan compound produced by a domesti
- Policy
- Opdivo's benefit extends for kidney cancer & parietal cancer
- by Lee, Hye-Kyung Aug 25, 2021 05:57am
- As domestic No. 1 immuno-cancer drug "Opdivo (Nivolumb)" renewed its contract with RSA, the benefit standard has also been expanded. The HIRA will issue a "proposal to revise the announcement of drugs prescribed and dispensed to cancer patients" and will inquire about their opinions by the 25th. If there is no disagreement, the benefit will b
- Opinion
- [Reporter's view] Controversy over α-GPC
- by Lee, Hye-Kyung Aug 25, 2021 05:57am
- Negotiations on the return of benefits of the 'Choline alfoscerate' legislation, which was the subject of the revaluation project of the listed drugs, have been concluded. However, the controversy over the return rate has not ended. The NHIS negotiated with 58 pharmaceutical companies that owned 123 Choline alfoscerate on August 10. It ann
- Policy
- Janssen’s acetaminophen tablets may replace Tylenol
- by Lee, Tak-Sun Aug 24, 2021 06:06am
- Janssen Korea, which locally manufactures and sells Tylenol in Korea, has received import authorization for its product. The company is presumed to be making the move to secure alternatives in advance before stopping the operation of its Hyangnam plan at the end of this year. On the 23rd, the Ministry of Food and Drug safety approved Jan
- Company
- Keytruda monopolizes the domestic pharmaceutical market
- by Chon, Seung-Hyun Aug 24, 2021 06:06am
- MSD's immuno-cancer drug Keytruda has taken the lead in the domestic pharmaceutical market for the sixth consecutive period since the first quarter of last year. New drugs recently released by domestic and foreign pharmaceutical companies such as Perjeta, Prolia, and K-CAB are growing. According to IQVIA, a pharmaceutical research firm on the
- Company
- Tylenol sales jump 140% due to the pandemic
- by Chon, Seung-Hyun Aug 24, 2021 06:05am
- Sales of the OTC antipyretic analgesic ‘Tylenol’ have soared. With the increased demand among people receiving the COVID-19 vaccinations, Tylenol sold &8361;43.6 billion in the first half of this year, which is twice more than that sold in the whole term of last year. There has been criticism that the government’s recommendation to take Tyle
